Tumor Infiltrating Lymphocytes (TIL) Therapy

Tumor-infiltrating lymphocyte (TIL) therapy is a type of cancer treatment that involves isolating and activating immune cells called TILs from a patient's tumor tissue, expanding them in the laboratory, and then infusing them back into the patient to target and attack cancer cells. One of the advantages of TIL therapy is that it can be personalized to each patient, as the TILs used in the treatment are derived from the patient's tumor tissue. In recent years, there have been advancements in next-generation TIL therapy, such as genetically engineering TILs to enhance their anti-tumor activity or improve their persistence within the tumor microenvironment. Genetically engineered TIL therapy holds great promise in expanding the therapeutic potential of TILs and improving outcomes for patients with cancer.

Fig.1 Strategies of TIL engineering.¹

TIL Platform

• TIL isolation from different tumor sources
• TIL culture and expansion using our proprietary manufacturing process
• Lentiviral vector transduction platform
• Gene editing platform

One-stop Services

The strategies of genetic modification of TILs include modifications to TILs to enhance their specificity, potency, resistance to suppression, homing capacity, and persistence, ultimately improving their efficacy in targeting and eliminating cancer cells. Our team of experts at Creative Biolabs is dedicated to developing next-generation TIL therapies. We provide several strategies for genetically modifying TILs to improve their anti-tumor activity.

• Modification with Genetic Adjuvants

Engineering TILs to release specific cytokines can enhance their anti-tumor activity by promoting inflammation and recruiting other immune cells to the tumor site.

• Increased Homing Capacity

Engineering TILs to express specific chemokine receptors like CCR4, CCR8, or CXCR2, can enhance their ability to improve their tumor-homing potential.

• Resistance to Immunosuppressive Signals

TILs can be engineered to resist signals from the tumor microenvironment that suppress their anti-tumor activity. For example, TILs that permanently silence PD-1 are more resistant to the immunosuppressive effects of tumor PD-L1 expression.

• Chimeric Antigen Receptor (CAR) TILs

CAR-TILs are engineered TILs that have been genetically modified to express specific chimeric antigen receptors on their surface. These modified receptors allow the TILs to recognize and target specific antigens present on the surface of cancer cells, leading to enhanced tumor cell killing and improved immune response against the tumor.

Workflow

Our Mission

As a pioneer in the field of engineered TIL therapies, Creative Biolabs is committed to driving innovation and advancing the boundaries of what is possible in cancer treatment. Our team of experts is committed to advancing the field of TIL therapy by providing innovative solutions for genetically modifying TILs. By combining these strategies, we aim to create next-generation TIL therapies that expand the therapeutic potential of TILs and offer great promise in preclinical and clinical studies.

Reference

1. Jiménez-Reinoso, Anaïs, et al. "Synthetic TILs: engineered tumor-infiltrating lymphocytes with improved therapeutic potential." Frontiers in Oncology 10 (2021): 593848.

For Research Use Only | Not For Clinical Use